{"Title": "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) Inhibitor, in patients with advanced solid tumors", "Year": 2015, "Source": "Clin. Cancer Res.", "Volume": "21", "Issue": 1, "Art.No": null, "PageStart": 77, "PageEnd": 86, "CitedBy": 161, "DOI": "10.1158/1078-0432.CCR-14-0947", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84920538174&origin=inward", "Abstract": "\u00a92014 AACR.Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K). Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels. Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue. Results: Pictilisib was well tolerated. The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients). The pharmacokinetic profile was dose-proportional and supported once-daily dosing. Levels of phosphorylated serine-473 AKT were suppressed >90%in PRP at 3 hours after dose at the MTD and in tumor at pictilisib doses associated with AUC >20 h\u00b7\u03bcmol/L. Signi ficant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation. A patient with V600E BRAF- mutant melanoma and another with platinumrefractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively. Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels \u2265100 mg and signs of antitumor activity. The recommended phase II dose was continuous dosing at 330 mg once-daily.", "AuthorKeywords": null, "IndexKeywords": ["Administration, Oral", "Adult", "Aged", "Dose-Response Relationship, Drug", "Drug-Related Side Effects and Adverse Reactions", "Female", "Humans", "Indazoles", "Male", "Maximum Tolerated Dose", "Middle Aged", "Neoplasms", "Phosphatidylinositol 3-Kinases", "Protein Kinase Inhibitors", "Proto-Oncogene Proteins B-raf", "Sulfonamides"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84920538174", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"24073399100": {"Name": "Sarker D.", "AuthorID": "24073399100", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "24528412100": {"Name": "Ang J.E.", "AuthorID": "24528412100", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "7201567425": {"Name": "Baird R.", "AuthorID": "7201567425", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "8771515300": {"Name": "Kristeleit R.", "AuthorID": "8771515300", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "57214656549": {"Name": "Shah K.", "AuthorID": "57214656549", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "57218668791": {"Name": "Moreno V.", "AuthorID": "57218668791", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "55415144200": {"Name": "Kaye S.B.", "AuthorID": "55415144200", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "7003906526": {"Name": "De Bono J.S.", "AuthorID": "7003906526", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "55793189394": {"Name": "Clarke P.A.", "AuthorID": "55793189394", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "7005112706": {"Name": "Raynaud F.I.", "AuthorID": "7005112706", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "7102917811": {"Name": "Workman P.", "AuthorID": "7102917811", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "57214279046": {"Name": "Levy G.", "AuthorID": "57214279046", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "7201751994": {"Name": "Ware J.A.", "AuthorID": "7201751994", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "6602398307": {"Name": "Mazina K.", "AuthorID": "6602398307", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "56470151100": {"Name": "Lin R.", "AuthorID": "56470151100", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "55452385600": {"Name": "Wu J.", "AuthorID": "55452385600", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "56470411400": {"Name": "Fredrickson J.", "AuthorID": "56470411400", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "36769281000": {"Name": "Spoerke J.M.", "AuthorID": "36769281000", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "8350048700": {"Name": "Lackner M.R.", "AuthorID": "8350048700", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "36986442900": {"Name": "Yan Y.", "AuthorID": "36986442900", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "7403040201": {"Name": "Friedman L.S.", "AuthorID": "7403040201", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "6507730069": {"Name": "Derynck M.K.", "AuthorID": "6507730069", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}}}